Celularity Stock EBITDA
| CELU Stock | USD 2.04 0.03 1.49% |
Celularity fundamentals help investors to digest information that contributes to Celularity's financial success or failures. It also enables traders to predict the movement of Celularity Stock. The fundamental analysis module provides a way to measure Celularity's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Celularity stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 27.1 M | 28.5 M |
Celularity | EBITDA |
Celularity Company EBITDA Analysis
Celularity's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Celularity EBITDA | (35.91 M) |
Most of Celularity's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Celularity is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Celularity EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Celularity is extremely important. It helps to project a fair market value of Celularity Stock properly, considering its historical fundamentals such as EBITDA. Since Celularity's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Celularity's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Celularity's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Celularity Ebitda
Ebitda |
|
According to the company disclosure, Celularity reported earnings before interest,tax, depreciation and amortization of (35.91 Million). This is 104.09% lower than that of the Biotechnology sector and 135.85% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.92% higher than that of the company.
Celularity EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Celularity's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Celularity could also be used in its relative valuation, which is a method of valuing Celularity by comparing valuation metrics of similar companies.Celularity is currently under evaluation in ebitda category among its peers.
Celularity ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Celularity's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Celularity's managers, analysts, and investors.Environmental | Governance | Social |
Celularity Institutional Holders
Institutional Holdings refers to the ownership stake in Celularity that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Celularity's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Celularity's value.| Shares | Ubs Group Ag | 2024-09-30 | 6 K | Simplex Trading, Llc | 2024-09-30 | 3.5 K | Bank Of America Corp | 2024-06-30 | 2.3 K | Tower Research Capital Llc | 2024-09-30 | 1.6 K | Ifp Advisors, Llc | 2024-06-30 | 1000 | Corecap Advisors, Llc | 2024-09-30 | 500 | Global Retirement Partners, Llc. | 2024-09-30 | 300 | Weaver Capital Management, Llc | 2024-09-30 | 300 | Financial Perspectives Inc | 2024-09-30 | 171 | Vanguard Group Inc | 2024-09-30 | 500.1 K | Geode Capital Management, Llc | 2024-09-30 | 137.5 K |
Celularity Fundamentals
| Return On Equity | -1.54 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (2.64) % | ||||
| Operating Margin | (0.84) % | ||||
| Current Valuation | 111.78 M | ||||
| Shares Outstanding | 22.01 M | ||||
| Shares Owned By Insiders | 50.39 % | ||||
| Shares Owned By Institutions | 14.84 % | ||||
| Number Of Shares Shorted | 934.46 K | ||||
| Price To Earning | 3.08 X | ||||
| Price To Book | 1.61 X | ||||
| Price To Sales | 1.05 X | ||||
| Revenue | 22.77 M | ||||
| Gross Profit | (1.69 M) | ||||
| EBITDA | (35.91 M) | ||||
| Net Income | (196.29 M) | ||||
| Cash And Equivalents | 42.65 M | ||||
| Cash Per Share | 0.29 X | ||||
| Total Debt | 39.24 M | ||||
| Debt To Equity | 0.41 % | ||||
| Current Ratio | 0.91 X | ||||
| Book Value Per Share | 1.27 X | ||||
| Cash Flow From Operations | (38.69 M) | ||||
| Short Ratio | 0.36 X | ||||
| Earnings Per Share | (104.78) X | ||||
| Target Price | 2.5 | ||||
| Number Of Employees | 120 | ||||
| Beta | 0.51 | ||||
| Market Capitalization | 44.89 M | ||||
| Total Asset | 143.89 M | ||||
| Retained Earnings | (841.79 M) | ||||
| Working Capital | (47.51 M) | ||||
| Net Asset | 143.89 M |
About Celularity Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Celularity's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Celularity using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Celularity based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Celularity Stock Analysis
When running Celularity's price analysis, check to measure Celularity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celularity is operating at the current time. Most of Celularity's value examination focuses on studying past and present price action to predict the probability of Celularity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celularity's price. Additionally, you may evaluate how the addition of Celularity to your portfolios can decrease your overall portfolio volatility.